ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,445.80
0.21%
Dow Jones
39,856.15
0.75%
Gold vs US Dollar
2,388.16
1.39%
Brent Oil
82.635
0.10%
Bitcoin
65,189.38
5.92%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. IO Biotech Inc (IOBT)

  7. IO Biotech Inc (IOBT) News

IO Biotech (IOBT)

IO Biotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IOBT
DateTimeSourceHeadlineSymbolCompany
14/05/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
14/05/202413:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
14/05/202412:55GlobeNewswire Inc.IO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
24/04/202421:30GlobeNewswire Inc.IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:IOBTIO Biotech Inc
15/04/202413:30GlobeNewswire Inc.IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessNASDAQ:IOBTIO Biotech Inc
09/04/202417:00GlobeNewswire Inc.IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103NASDAQ:IOBTIO Biotech Inc
05/04/202413:30GlobeNewswire Inc.IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerNASDAQ:IOBTIO Biotech Inc
11/03/202420:56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IOBTIO Biotech Inc
06/03/202421:11GlobeNewswire Inc.IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IOBTIO Biotech Inc
05/03/202422:17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IOBTIO Biotech Inc
05/03/202421:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
05/03/202421:40GlobeNewswire Inc.IO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsNASDAQ:IOBTIO Biotech Inc
26/02/202421:05GlobeNewswire Inc.IO Biotech to Present at 44th Annual Cowen Health Care ConferenceNASDAQ:IOBTIO Biotech Inc
08/01/202413:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
21/12/202313:30GlobeNewswire Inc.IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialNASDAQ:IOBTIO Biotech Inc
24/11/202322:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
13/11/202321:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
13/11/202313:12GlobeNewswire Inc.IO Biotech Announces 2023 Third Quarter ResultsNASDAQ:IOBTIO Biotech Inc
13/11/202313:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
13/11/202313:00GlobeNewswire Inc.IO Biotech Appoints Helen Collins, MD, to its Board of DirectorsNASDAQ:IOBTIO Biotech Inc
10/11/202313:00GlobeNewswire Inc.IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced MelanomaNASDAQ:IOBTIO Biotech Inc
08/11/202321:30GlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
01/11/202312:30GlobeNewswire Inc.IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:IOBTIO Biotech Inc
23/10/202306:00GlobeNewswire Inc.Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European SocieNASDAQ:IOBTIO Biotech Inc
03/10/202321:30GlobeNewswire Inc.IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:IOBTIO Biotech Inc
12/09/202321:06Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:IOBTIO Biotech Inc
12/09/202313:05GlobeNewswire Inc.IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung CancerNASDAQ:IOBTIO Biotech Inc
11/09/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IOBTIO Biotech Inc
07/09/202315:36Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IOBTIO Biotech Inc
06/09/202313:35GlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:IOBT

Your Recent History

EU
C162S
C162S
COIN
NCASHETH
Nucleus Vision
BOV
SNSY3Q
SANSUY ON
GATE
ALNETH
Aluna
USOTC
KIARF
Kiaro (CE)
BIT
UB1C6Z
Unicredit Bank
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved